KLİNİK ÇALIŞMALAR
  • Carey E et al. Second Look at Utilization of a Closed-System Transfer Device (PhaSeal). Am J Pharm Benefits. 2011;3(6):311-318.                 
  • Connor T, Anderson R, Sessink P et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an I.V. admixture area. Am J Health Syst Pharm.2002; 59: 68-72.                
  • Gustavsson B. Evaluation of technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract. 1997; 3:46.                            
  • Harrison B, Peters B, Bing M. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm. 2006; 63: 1736-1744.                              
  • Jorgenson J, Spivey S, Au C et al. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2008; 43(9): 723-727                          
  • Jorgenson J. Leakproof connection integrity test for devices intended for handling hazardous drugs.(Presented at ASHP Midyear Clinical Meeting, December 2007.)                      
  • Jorgenson J. 2007 Utah protocol update: evaluation of vial transfer devices for containment of hazardous drug vapors. (Presented at ASHP Midyear Clinical Meeting, December 2007.)            
  • McDiarmid M., Oliver M., Rogers B., et al. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. JOEM. 2010; 52(10): 1028-1034.                 
  • McMichael D, Jefferson D, Carey E et al. Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits. 2011; 3(1): 9-16.                              
  • Nishigaki R, Konno E, Sugiyasu M et al. The usefulness of a closed-system device for the mixing of injections to prevent occupational exposure to anticancer drugs. Journal of Japanese Society of Hospital Pharmacists. 2010; 46(1): 113-117.                              
  • Nyman H, Jorgenson J, Slawson M. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007; 42(3): 219-225.              
  • Sessink P, Rolf M, Rydén S. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm.1999; 34: 1311-1317.                    
  • Spivey S, Connor T. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003; 38(2): 135-139.                      
  • Vandenbroucke J, Robays H. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. EJHP Practice. 2008; 14(5): 37-42.                           
  • Wick C, Slawson M, Jorgenson J et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60: 2314-2320.